Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 7, 2022 | Series B | — | 2 | — | — | Detail |
Jan 20, 2021 | Series B | — | 1 | — | — | Detail |
Feb 24, 2020 | Series B | $165M | 5 | SoftBank Vision Fund | — | Detail |
Nov 30, 2018 | Debt Financing | $25M | 1 | Oxford Finance LLC | — | Detail |
Aug 5, 2017 | Series A | $59M | 8 | DCVC Lightspeed Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SoftBank Vision Fund | Yes | Series B |
Oxford Finance LLC | Yes | Debt Financing |
DCVC | Yes | Series A |
HBM Healthcare Investments AG | — | Series B |
HBM Partners | — | Series B |
General Catalyst | — | Series B |
Khosla Ventures | — | Series B |
Lightspeed Venture Partners | — | Series B |
aMoon Fund | — | Series A |
Innovation Endeavors | — | Series A |